Table 1. Rates of SVR for patients with compensated cirrhosis HCV genotype 1 (phase III/IV studies).
| Regimen | Duration | Patients | SVR rate | Study (reference) |
|---|---|---|---|---|
| LDV – SOF ± RBV | 12–24 weeks | Naïve | 97–100% | ION-1 21 |
| LDV – SOF ± RBV | 12–24 weeks | TE | 82–100% | ION-2 20 |
| LDV – SOF
LDV – SOF - RBV |
24 weeks
12 weeks |
TE
TE |
97%
96% |
SIRIUS 84 |
| SIM – SOF | 12 weeks | Naïve
TE |
88%
79% |
OPTIMIST-2
22
|
| SIM – SOF ± RBV
|
12 weeks
|
Naïve
TE |
75%
73–88% |
Trio Network
85
|
| SIM – SOF ± RBV
|
12 weeks
|
Naïve
TE |
87–93%
80–82% |
HCV-Target
86
|
| OMB – PAR/r – DSV + RBV
|
12–24 weeks
|
Naïve
TE |
94–95%
90–97% |
TURQUOSE-II
23
|
| OMB – PAR/r – DSV | 12 weeks | TE | 100% | TURQUOSE-III 24 |
| GPV – ELB | 12 weeks | Naïve | 97% | C-EDGE 87 |
| SIM – SOF
|
12 weeks
|
Naïve
TE |
95%
92% |
Pearlman
et al.
88
|
| SIM – SOF
|
12 weeks
|
Naïve
TE |
83%
|
Aqel
et al.
89
|
| SIM – SOF ± RBV
|
12 weeks
|
Naïve
TE |
91–94%
88–95% |
Saxena
et al.
46
|
| SIM – SOF | 12 weeks | Naïve and TE | 87% | Shiffman et al. 90 |
| DCV – ASV – BCV ± RBV | 12 weeks | Naïve and TE | 87–98% | Unity-2 91 |
| VPV – SOF | 12 weeks | Naïve and TE | 99% | ASTRAL-1 45 |
a. Abbreviations: ASV, asunaprevir; BCV; beclabuvir; DCV, daclatasvir; DSV, dasabuvir; ELB, elbasvir; GPV, grazoprevir; HCV, hepatitis C virus; LDV, ledipasvir; OMB, ombitasvir; PAR/r, paritaprevir/ritonavir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; VPV, velpatasvir